Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Sep 29;14(1):67.
doi: 10.1186/s12954-017-0192-8.

Perceived benefits of the hepatitis C peer educators: a qualitative investigation

Affiliations

Perceived benefits of the hepatitis C peer educators: a qualitative investigation

A W Batchelder et al. Harm Reduct J. .

Abstract

Background: Although opioid-dependent patients are disproportionately impacted by hepatitis C (HCV), many do not receive treatment. In addition to HCV treatment-access barriers, substance-using patients may be reluctant to pursue treatment because of wariness of the medical system, lack of knowledge, or stigma related to HCV treatment. Implementation of a formal peer education program is one model of reducing provider- and patient-level barriers to HCV treatment, by enhancing mutual trust and reducing stigma.

Methods: We used thematic qualitative analysis to explore how 30 HCV patients and peer educators perceived a HCV peer program within an established methadone maintenance program in the USA.

Results: Participants unanimously described the program as beneficial. Participants described the peer educators' normalization and dispelling of myths and fears around HCV treatment, and their exemplification of HCV treatment success, and reductions in perceived stigma. Peer educators described personal benefits.

Conclusions: These findings indicate that HCV peer educators can enhance HCV treatment initiation and engagement within opioid substitution programs.

Keywords: Hepatitis C; Methadone; Peer; Peer educator; Treatment.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

This work was approved by the Albert Einstein College of Medicine’s Institutional Review Board, and all participants completed informed consent.

Consent for publication

All participants completed informed consent, which included a description of publishing de-identified components of the transcribed interviews.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Similar articles

Cited by

References

    1. Edlin BR, Eckhardt BJ, Shu MA, Holmberg SD, Swan T. Toward a more accurate estimate of the prevalence of hepatitis C in the United States. Hepatology. 2015;62(5):1353–1363. doi: 10.1002/hep.27978. - DOI - PMC - PubMed
    1. Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm. Accessed 20 Sept 2017.
    1. McCarthy JJ, Flynn N. Hepatitis C in methadone maintenance patients: prevalence and public policy implications. J Addict Dis. 2001;20(1):19–31. doi: 10.1300/J069v20n01_03. - DOI - PubMed
    1. Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend. 2001;61(3):211–215. doi: 10.1016/S0376-8716(00)00144-7. - DOI - PubMed
    1. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364(25):2405–2416. doi: 10.1056/NEJMoa1012912. - DOI - PubMed

Publication types